Idorsia Ltd

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Subsidiary

Employees: -

Market Cap: $464M

Website: http://www.idorsia.com

Clinical Trials

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Phase 3

Completed

Conditions: Insomnia Disorder

Interventions: Other: Placebo
Drug: Daridorexant

First Posted Date: 2018-07-02

Last Posted Date: 2022-03-25

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 924

Registration Number: NCT03575104

Locations: 🇨🇦
Canadian Phase Onward Inc., Toronto, Ontario, Canada
🇺🇸
FutureSearch Trials of Neurology, LP, Austin, Texas, United States
🇺🇸
Neurotrials Research Incorporated, Atlanta, Georgia, United States

and more 82 locations

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Phase 3

Completed

Conditions: Insomnia Disorder

Interventions: Drug: Daridorexant 50 mg
Other: Placebo
Drug: Daridorexant 25 mg

First Posted Date: 2018-06-04

Last Posted Date: 2022-03-25

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 930

Registration Number: NCT03545191

Locations: 🇺🇸
PAB Clinical Research, Brandon, Florida, United States
🇩🇪
Klinische Forschung Hamburg GmbH, Hamburg, Germany
🇩🇪
emovis GmbH, Berlin, Germany

and more 78 locations

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

Phase 3

Completed

Conditions: Resistant Hypertension

Interventions: Drug: Aprocitentan 25 mg
Drug: Placebo
Drug: Aprocitentan 12.5 mg

First Posted Date: 2018-05-30

Last Posted Date: 2023-03-21

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 730

Registration Number: NCT03541174

Locations: 🇺🇸
TLM Medical Services LLC, Columbia, South Carolina, United States
🇺🇸
Academic Medical Research Institute Inc, Los Angeles, California, United States
🇺🇸
California Kidney Specialists, San Dimas, California, United States

and more 156 locations

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Phase 2

Completed

Conditions: Acute Myocardial Infarction

Interventions: Drug: Selatogrel 8 mg
Drug: Selatogrel 16 mg

First Posted Date: 2018-04-04

Last Posted Date: 2022-11-17

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 48

Registration Number: NCT03487445

Locations: 🇮🇱
Galilee Medical Center, Nahariya, Israel
🇧🇪
OLV Ziekenhuis Aalst, Aalst, Belgium
🇧🇪
UZLeuven, Leuven, Belgium

and more 3 locations

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-246475
Drug: Clopidogrel
Drug: Prasugrel
Drug: Placebo
Drug: Ticagrelor

First Posted Date: 2018-02-13

Last Posted Date: 2022-11-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 77

Registration Number: NCT03430661

Locations: 🇺🇸
Biotrial Inc, Newark, New Jersey, United States

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

Phase 3

Completed

Conditions: Fabry Disease

Interventions: Drug: Placebo
Drug: Lucerastat

First Posted Date: 2018-02-07

Last Posted Date: 2024-08-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 118

Registration Number: NCT03425539

Locations: 🇺🇸
Emory University School of Medicine; Department of Human Genetics, Atlanta, Georgia, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States

and more 46 locations

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Phase 2

Completed

Conditions: Stable Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Selatogrel

First Posted Date: 2017-12-28

Last Posted Date: 2022-11-17

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 346

Registration Number: NCT03384966

Locations: 🇺🇸
University of Florida (UF) Jacksonville, Jacksonville, Florida, United States
🇺🇸
Florida Hospital Tampa - Pepin Heart Institute, Tampa, Florida, United States
🇺🇸
NorthShore University, Chicago, Illinois, United States

and more 17 locations

Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Lucerastat
Drug: Cimetidine

First Posted Date: 2017-12-21

Last Posted Date: 2022-06-02

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 14

Registration Number: NCT03380455

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo oral capsule
Drug: ID-085

First Posted Date: 2017-12-13

Last Posted Date: 2018-12-19

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 88

Registration Number: NCT03372629

Locations: 🇬🇧
Covance Clinical Research Unit - Clinical Pharmacology Services, Leeds, United Kingdom

Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: ID-082

First Posted Date: 2017-12-06

Last Posted Date: 2018-06-27

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 20

Registration Number: NCT03363984

Locations: 🇬🇧
Simbec Research Limited, Merthyr Tydfil, Mid Galmorgan, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy